Dr. Giermasz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2279 45th St.
Uc Davis, Comprehensive Cancer Center
Sacramento, CA 95817Phone+1 415-514-0269- Is this information wrong?
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2008 - 2011
UPMC Medical EducationResidency, Internal Medicine, 2005 - 2008
Medical University of WarsawClass of 1998
Certifications & Licensure
CA State Medical License 2008 - 2026
PA State Medical License 2005 - 2008- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- 1 citationsGiroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.Andrew D Leavitt, Barbara A Konkle, Kimo C Stine, Nathan Visweshwar, Thomas J Harrington, Adam Giermasz, Steven Arkin, Annie Fang, Frank Plonski, Anne Yver, Florence G...> ;Blood. 2024 Feb 29
- 1 citationsHealth-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.Brian O'Mahony, Amy L Dunn, Andrew D Leavitt, Flora Peyvandi, Margareth C Ozelo, Johnny Mahlangu, Kathelijne Peerlinck, Jiaan-Der Wang, Gillian C Lowe, Chee Wee Tan, A...> ;Journal of Thrombosis and Haemostasis. 2023 Dec 1
- 11 citationsStable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.Annette von Drygalski, Esteban Gomez, Adam Giermasz, Giancarlo Castaman, Nigel S Key, Susan U Lattimore, Frank W G Leebeek, Wolfgang A Miesbach, Michael Recht, Robert ...> ;Blood Advances. 2023 Oct 10
- Join now to see all
Abstracts/Posters
- Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patien...Adam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia BAdam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 YearAdam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
ASH 2020: Update for the Alta Study, a Phase 1/2 Gene Therapy Trial of Giroctocogene Fitelparvovec (SB-525) in Adults with Severe Hemophilia ADecember 18th, 2020
Hospital Affiliations
UC Davis Medical CenterSacramento, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
